Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy: Effect on nerve function

Journal of Diabetes and Its Complications

Volumn 7, Issue 3, 1993, Pages 170-178

  Santiago, Julio V ^a   Sönksen, Peter H ^b   Boulton, Andrew J M ^c   Macleod, Andrew ^b   Beg, Mirza ^d   Bochenek, Wieslaw ^d   Graepel, G Jay ^d   Gonen, Boas ^d  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

^d WYETH AYERST RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; PLACEBO; TOLRESTAT;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEUROPATHY; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NERVE CONDUCTION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ALDEHYDE REDUCTASE; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; DOUBLE-BLIND METHOD; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MEDIAN NERVE; MIDDLE AGED; NAPHTHALENES; NEURAL CONDUCTION; PAIN; PERIPHERAL NERVES; PLACEBOS; SURAL NERVE; ULNAR NERVE;

EID: 0027144914     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/1056-8727(93)90042-W     Document Type: Article

References (23)

1. Role of sorbitol pathway in neuropathy
2. Pathogenesis and prevention of diabetic neuropathy
3. Effect of blood sugar control on the accumulation of sorbitol and fructose in nervous tissue
4. Aldose reductase inhibitors in the treatment of diabetic neuropathy. A review of the rationale and clinical evidence
5. A multicentre trial of the aldose-reductase inhibitor, tolrestat, in patients with symptomatic diabetic neuropathy
6. Clinical studies with an aldose reductase inhibitor in the autonomic and somatic neuropathies of diabetes
7. Aldose reductase inhibition improves nerve conduction velocity in diabetic patients
8. Six-month treatment with sorbinil in asymptomatic diabetic neuropathy: Failure to improve abnormal nerve function
9. A multicentre trial of the aldose reductase inhibitor tolrestat in patients with symptomatic diabetic peripheral neuropathy
10. Human diabetic endoneural sorbitol, fructose, and myoinositol related to sural nerve morphometry
11. Nerve glucose, fructose, sorbitol, myo-inositol, and fiber degeneration and regeneration in diabetic neuropathy
12. Regeneration and repair of mylenated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil
13. Histopathological heterogeneity of neuropathy in insulin-dependent and non-insulin-dependent diabetes, and demonstration of axo-glial dysfunction in human diabetic neuropathy
14. Association of painful and painless diabetic polyneuropathy with different patterns of nerve fiber degeneration and regeneration
15. Diagnosis, staging, and classification of diabetic neuropathy and associations with other complications
16. Clinical and neuropathological criteria for the diagnosis and staging of diabetic polyneuropathy
17. Meaningful degrees of prevention or improvement of nerve conduction in controlled clinical trials of diabetic neuropathy
18. Biochemical and morphometric response to tolrestat in human diabetic nerve [Abstract]
19. Aldose reductase inhibitor treatment normalizes axo-glial dysjunction and improves nerve fiber pathology in advanced diabetic neuropathy [Abstract]
20. The effect of the aldose reductase inhibitor tolrestat on diabetic polyneuropathy: A meta-analysis [Abstract]
21. Procedures for comparing samples with multiple endpoints
22. Effects of aldose reductase inhibitor treatment in diabetic polyneuropathy—A clinical and neurophysical study
23. The relationship between sural nerve morphometric findings and measures of peripheral nerve function in mild diabetic neuropathy